Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia. The company was formerly known as Axovant Sciences Ltd. The company was founded in 2014 and is based in New York, New York. Axovant Gene Therapies Ltd. operates as a subsidiary of Roivant Sciences Ltd.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone833-296-8268
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees45
Next Earnings Date2/6/2020 (Estimated)
OptionableOptionable
Axovant Gene Therapies (NASDAQ:AXGT) Frequently Asked Questions
What is Axovant Gene Therapies' stock symbol?
Axovant Gene Therapies trades on the NASDAQ under the ticker symbol "AXGT."
When did Axovant Gene Therapies' stock split? How did Axovant Gene Therapies' stock split work?
Shares of Axovant Gene Therapies reverse split on the morning of Wednesday, May 8th 2019. The 1-8 reverse split was announced on Tuesday, May 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 7th 2019. An investor that had 100 shares of Axovant Gene Therapies stock prior to the reverse split would have 13 shares after the split.
How were Axovant Gene Therapies' earnings last quarter?
Axovant Gene Therapies Ltd (NASDAQ:AXGT) announced its quarterly earnings results on Friday, November, 8th. The company reported ($0.61) earnings per share for the quarter, beating analysts' consensus estimates of ($1.15) by $0.54. View Axovant Gene Therapies' Earnings History.
When is Axovant Gene Therapies' next earnings date?
What price target have analysts set for AXGT?
9 Wall Street analysts have issued 1 year target prices for Axovant Gene Therapies' shares. Their forecasts range from $5.79 to $56.00. On average, they expect Axovant Gene Therapies' stock price to reach $27.40 in the next year. This suggests a possible upside of 416.0% from the stock's current price. View Analyst Price Targets for Axovant Gene Therapies.
What is the consensus analysts' recommendation for Axovant Gene Therapies?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axovant Gene Therapies in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Axovant Gene Therapies.
What are Wall Street analysts saying about Axovant Gene Therapies stock?
Here are some recent quotes from research analysts about Axovant Gene Therapies stock:
- 1. According to Zacks Investment Research, "Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer's disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. " (11/13/2019)
- 2. Cowen Inc analysts commented, ". We reiterate our Overweight rating and $221 Price Target. Amgen posted an strong top-line at $5.56B vs Bloomberg consensus of $5.51B and a bottom-line beat with EPS of $3.56 vs consensus of $3.49. This also included the ASR of $3B in 1Q 2019. Key update was raising of the low end of revenue and EPS guidance, so range is now $22.0-22.9B and $13.25-14.30/sh from $21.8-22.9B and $13.10-$14.30/sh previously based on 1Q results. Though the company noted this reflects a range of outcomes for Sensipar, this adjustment suggests it had been accounting for the potential for additional top-line pressure in 1Q." (5/1/2019)
Has Axovant Gene Therapies been receiving favorable news coverage?
Media stories about AXGT stock have been trending negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Axovant Gene Therapies earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Axovant Gene Therapies.
Who are some of Axovant Gene Therapies' key competitors?
Some companies that are related to Axovant Gene Therapies include Molecular Templates (MTEM), Sinovac Biotech (SVA), Ardelyx (ARDX), ProQR Therapeutics (PRQR), DiaMedica Therapeutics (DMCAF), Aptorum Group (APM), Progenics Pharmaceuticals (PGNX), Assembly Biosciences (ASMB), BioSpecifics Technologies (BSTC), OrganiGram (OGI), Milestone Pharmaceuticals (MIST), Evolus (EOLS), Avedro (AVDR), INDIVIOR PLC/S (INVVY) and Atreca (BCEL).
What other stocks do shareholders of Axovant Gene Therapies own?
Who are Axovant Gene Therapies' key executives?
Axovant Gene Therapies' management team includes the folowing people:
- Dr. Pavan Cheruvu M.D., CEO & Director (Age 37)
- Dr. Gregory M. Weinhoff, Principal Financial & Accounting Officer (Age 48)
- Dr. David T. Hung M.D., Scientific Advisor of Group (Age 61)
- Dr. Fraser Wright, Chief Technology Officer
- Ms. Tricia Truehart, Head of Investor Relations
Who are Axovant Gene Therapies' major shareholders?
Axovant Gene Therapies' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (0.04%) and Barclays PLC (0.04%). Company insiders that own Axovant Gene Therapies stock include Atul Pande, Pavan Cheruvu and Svf Investments (Uk) Ltd. View Institutional Ownership Trends for Axovant Gene Therapies.
Which institutional investors are selling Axovant Gene Therapies stock?
Which institutional investors are buying Axovant Gene Therapies stock?
AXGT stock was bought by a variety of institutional investors in the last quarter, including Barclays PLC. Company insiders that have bought Axovant Gene Therapies stock in the last two years include Atul Pande, Pavan Cheruvu and Svf Investments (Uk) Ltd. View Insider Buying and Selling for Axovant Gene Therapies.
How do I buy shares of Axovant Gene Therapies?
Shares of AXGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Axovant Gene Therapies' stock price today?
One share of AXGT stock can currently be purchased for approximately $5.31.
How big of a company is Axovant Gene Therapies?
Axovant Gene Therapies has a market capitalization of $121.01 million. The company earns $-129,070,000.00 in net income (profit) each year or ($8.02) on an earnings per share basis. Axovant Gene Therapies employs 45 workers across the globe.View Additional Information About Axovant Gene Therapies.
What is Axovant Gene Therapies' official website?
How can I contact Axovant Gene Therapies?
Axovant Gene Therapies' mailing address is 11-12 ST. JAMES`S SQUARE SUITE 1 3RD FLOOR, LONDON X0, 10036. The company can be reached via phone at 833-296-8268 or via email at [email protected]
MarketBeat Community Rating for Axovant Gene Therapies (NASDAQ AXGT)
MarketBeat's community ratings are surveys of what our community members think about Axovant Gene Therapies and other stocks. Vote "Outperform" if you believe AXGT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXGT will underperform the S&P 500 over the long term. You may vote once every thirty days.
